Recombinant monoclonal antibody against mouse and human CXCL12α, CXCL12β, and CXCL12γ, was shown to dose-dependently block CXCL12α binding to CXCR4 and CXCR7, and CXCL12α-induced Jurkat cell migration in vitro.
Figure 1 Characterization of hamster anti-CXCL12 antibodies.
Dose-dependent inhibition of CXCL12α-induced Jurkat cell migration in the absence or presence of various concentrations of hamster antibodies. Of note, 10 ng/mL human CXCL12α was preincubated with antibodies in serial 1:3 dilutions at room temperature for 30 minutes. The highest concentration used for each antibody is shown. IC₅₀ was the average of 3 independent experiments. Data are expressed as mean ± SD.
Zhong, C., Wang, J., Li, B., Xiang, H., Ultsch, M., Coons, M., ... & Quintana, L. (2013). Development and preclinical characterization of a humanized antibody targeting CXCL12. Clinical Cancer Research, 19(16), 4433-4445.
Figure 2 Characterization of hamster anti-CXCL12 antibodies.
Effects of 30D8 on CXCL12α-induced Jurkat cell Rac activation. Jurkat cells were treated with 100 ng/mL human CXCL12α for 10 minutes in the presence of various concentrations of 30D8, 46H9, 18E9, or control hamster antibody, MAB170 or AMD3100, as indicated. The total and GTP-bound Rac1 were detected by Western blotting using an antibody against Rac1. Data were representative of 3 independent studies.
Zhong, C., Wang, J., Li, B., Xiang, H., Ultsch, M., Coons, M., ... & Quintana, L. (2013). Development and preclinical characterization of a humanized antibody targeting CXCL12. Clinical Cancer Research, 19(16), 4433-4445.
Figure 3 Effects of 30D8 in various mouse tumor models, alone or in combination with anti-VEGF antibody B20.4.1.1 (B20).
Percentage of F4/80+, CD11b+/Gr1+, and CD31+ cells in EL4 tumors treated with control antibody, 30D8, or B20.4.1.1 at day 10 after tumor cell implantation using FACS. Five tumors per treatment group were used and stained with appropriate antibodies.
Zhong, C., Wang, J., Li, B., Xiang, H., Ultsch, M., Coons, M., ... & Quintana, L. (2013). Development and preclinical characterization of a humanized antibody targeting CXCL12. Clinical Cancer Research, 19(16), 4433-4445.
Figure 4 Effects of 30D8 in various mouse tumor models, alone or in combination with anti-VEGF antibody B20.4.1.1 (B20).
All antibodies were administered intraperitoneally. A, dose-dependent efficacy of 30D8 in the EL4 model. C57BL6 mice (n = 10/group) bearing EL4 tumors were treated with 30D8 at various doses (three times/week), with or without anti-VEGF antibody B20.4.1.1 at 10 mg/kg (twice/week). Hamster antibody gD:2566 served as a control antibody for 30D8. Tumor size was measured at day 3, 5, 8, 10, and 12.
Zhong, C., Wang, J., Li, B., Xiang, H., Ultsch, M., Coons, M., ... & Quintana, L. (2013). Development and preclinical characterization of a humanized antibody targeting CXCL12. Clinical Cancer Research, 19(16), 4433-4445.
Figure 5 Pharmacokinetic profiles of 30D8.
30D8 serum concentration–time profiles after a single intraperitoneal administration in Balb/c nude mice at 30 mg/kg (n = 3/time point with a total of n = 9/group). Serum was collected at various time points, up to 7 days after 30D8 administration. Total hamster IgG1 levels were measured by a generic hamster antibody ELISA.
Zhong, C., Wang, J., Li, B., Xiang, H., Ultsch, M., Coons, M., ... & Quintana, L. (2013). Development and preclinical characterization of a humanized antibody targeting CXCL12. Clinical Cancer Research, 19(16), 4433-4445.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-256-S(P) | Recombinant Anti-human CXCL12 Antibody scFv Fragment | IP, IF, Biosensors, FuncS | scFv |
MHH-256-S(P) | Recombinant Human Anti-human CXCL12 Antibody scFv Fragment | ELISA, WB, IF, FuncS | scFv |
PSBL-057 | Human Anti-CXCL12 Recombinant Antibody; scFv Fragment (PSBL-057) | FC, ELISA, FuncS | Human scFv |
HPAB-632-FY-S(P) | Mouse Anti-CXCL12 Recombinant Antibody; scFv Fragment (HPAB-632-FY-S(P)) | Inhib | Mouse scFv |
HPAB-633-FY-S(P) | Mouse Anti-CXCL12 Recombinant Antibody; scFv Fragment (HPAB-633-FY-S(P)) | Block | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-040 | Recombinant Anti-Human CXCL12 VHH Single Domain Antibody | WB, ELISA, IHC, FuncS | Llama VHH |
HPAB-0348-YC-VHH | Llama Anti-CXCL12 Recombinant Antibody; VHH Fragment (HPAB-0348-YC-VHH) | FuncS | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
PABL-057 | Human Anti-CXCL12 Recombinant Antibody (PABL-057) | FC, ELISA, FuncS | Human IgG |
MOB-1847CT | Recombinant Mouse anti-Human CXCL12 Monoclonal antibody (NN0322-0O37) | FC, IHC-P | |
MRO-1371-CN | Rabbit Anti-CXCL12 Recombinant Antibody (clone CBACN-498) | WB, IF | Rabbit IgG |
HPAB-632-FY | Human Anti-CXCL12 Recombinant Antibody (HPAB-632-FY) | Inhib | Chimeric (Mouse/Human) IgG2a |
HPAB-633-FY | Human Anti-CXCL12 Recombinant Antibody (HPAB-633-FY) | Block | Chimeric (Mouse/Human) IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-057 | Human Anti-CXCL12 Recombinant Antibody; Fab Fragment (PFBL-057) | FC, ELISA, FuncS | Human Fab |
HPAB-0050LY-F(E) | Human Anti-CXCL12 Recombinant Antibody; Fab Fragment (HPAB-0050LY-F(E)) | Block, ELISA, WB, RIA, FC | Human Fab |
HPAB-0051LY-F(E) | Human Anti-CXCL12 Recombinant Antibody; Fab Fragment (HPAB-0051LY-F(E)) | Block, ELISA, WB, RIA, FC | Human Fab |
HPAB-0052LY-F(E) | Human Anti-CXCL12 Recombinant Antibody; Fab Fragment (HPAB-0052LY-F(E)) | Block, ELISA, WB, RIA, FC | Human Fab |
HPAB-0053LY-F(E) | Human Anti-CXCL12 Recombinant Antibody; Fab Fragment (HPAB-0053LY-F(E)) | Block, ELISA, WB, RIA, FC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-416CT | Anti-Human CXCL12 Recombinant Antibody (hu30D8) | Funcs, FC, PK, ELISA, Neut, WB | Humanized antibody |
TAB-416CT-S(P) | Anti-Human CXCL12 Recombinant Antibody scFv Fragment (hu30D8) | WB, ELISA, Neut, FC | Humanized antibody |
TAB-416CT-F(E) | Anti-Human CXCL12 Recombinant Antibody Fab Fragment (hu30D8) | WB, ELISA, Neut, FC | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-415CT-S(P) | Anti-Human CXCL12 Recombinant Antibody scFv Fragment (30D8) | WB, ELISA, Neut, FC | |
TAB-415CT-F(E) | Anti-Human CXCL12 Recombinant Antibody Fab Fragment (30D8) | WB, ELISA, Neut, FC |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-417CT-S(P) | Human Anti-CXCL12 Recombinant Antibody; scFv Fragment (TAB-417CT-S(P)) | BL, WB, ELISA | Human scFv |
TAB-417CT-F(E) | Human Anti-CXCL12 Recombinant Antibody; Fab Fragment (TAB-417CT-F(E)) | BL, WB, ELISA | Human Fab |
TAB-418CT-F(E) | Human Anti-CXCL12 Recombinant Antibody; Fab Fragment (TAB-418CT-F(E)) | BL, WB, ELISA | Human Fab |
TAB-419CT-F(E) | Human Anti-CXCL12 Recombinant Antibody; Fab Fragment (TAB-419CT-F(E)) | BL, WB, ELISA | Human Fab |
TAB-420CT-F(E) | Human Anti-CXCL12 Recombinant Antibody; Fab Fragment (TAB-420CT-F(E)) | BL, WB, ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-612CQ | Mouse Anti-CXCL12 Recombinant Antibody (clone CBL825) | Neut | Mouse IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0884 | Hi-Affi™ Rabbit Anti-CXCL12 Recombinant Antibody (clone DS884AB) | WB, ICC, IF | Rabbit IgG |
There are currently no Customer reviews or questions for TAB-415CT. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.